{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T09:20:12Z","timestamp":1697361612734},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Gastro"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1007\/s11938-005-0016-x","type":"journal-article","created":{"date-parts":[[2007,6,3]],"date-time":"2007-06-03T14:42:27Z","timestamp":1180881747000},"page":"239-247","source":"Crossref","is-referenced-by-count":9,"title":["Chemotherapy of metastatic colorectal cancer"],"prefix":"10.1007","volume":"8","author":[{"given":"Everardo D.","family":"Saad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo M.","family":"Hoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"16_CR1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3322\/canjclin.49.1.33","volume":"49","author":"DM Parkin","year":"1999","unstructured":"Parkin DM, Pisani P, Ferlay J: Global cancer statistics. CA Cancer J Clin 1999, 49: 33\u201364.","journal-title":"CA Cancer J Clin"},{"key":"16_CR2","volume-title":"World Cancer Report","year":"2003","unstructured":"Stewart BW, Kleihues P, editors. World Cancer Report. Lyon: IARC Press; 2003."},{"key":"16_CR3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3322\/canjclin.54.1.8","volume":"54","author":"A Jemal","year":"2004","unstructured":"Jemal A, Tiwari RC, Murray T, et al.: Cancer statistics, 2004. CA Cancer J Clin 2004, 54: 8\u201329.","journal-title":"CA Cancer J Clin"},{"key":"16_CR4","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1634\/theoncologist.8-6-541","volume":"8","author":"LA Gloeckler Ries","year":"2003","unstructured":"Gloeckler Ries LA, Reichman ME, Lewis DR, et al.: Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 2003, 8: 541\u2013552.","journal-title":"Oncologist"},{"key":"16_CR5","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","volume":"3","author":"DB Longley","year":"2003","unstructured":"Longley DB, Harkin DP, Johnston PG: 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003, 3: 330\u2013338.","journal-title":"Nat Rev Cancer"},{"key":"16_CR6","doi-asserted-by":"crossref","unstructured":"Anonymous: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 1992, 10:896\u2013903.","DOI":"10.1200\/JCO.1992.10.6.896"},{"key":"16_CR7","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/jco.2004.22.14_suppl.7233","volume":"22","author":"P Thirion","year":"2004","unstructured":"Thirion P, Michiels S, Pignon JP, et al.: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004, 22: 3766\u20133775.","journal-title":"J Clin Oncol"},{"key":"16_CR8","doi-asserted-by":"crossref","unstructured":"Anonymous: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer. J Clin Oncol 1998, 16:301\u2013308.","DOI":"10.1200\/JCO.1998.16.1.301"},{"key":"16_CR9","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1136\/bmj.321.7260.531","volume":"321","author":"PC Simmonds","year":"2000","unstructured":"Simmonds PC: Palliative chemotherapy for advanced colorectal cancer: systematic review and metaanalysis. Colorectal Cancer Collaborative Group. BMJ 2000, 321: 531\u2013535.","journal-title":"BMJ"},{"key":"16_CR10","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1054\/bjoc.1999.1254","volume":"82","author":"DJ Jonker","year":"2000","unstructured":"Jonker DJ, Maroun JA, Kocha W: Survival benefit of chemotherapy in metastatic colorectal cancer: a meta-analysis of randomized controlled trials. Br J Cancer 2000, 82: 1789\u20131794.","journal-title":"Br J Cancer"},{"key":"16_CR11","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","volume":"355","author":"JY Douillard","year":"2000","unstructured":"Douillard JY, Cunningham D, Roth AD, et al.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000, 355: 1041\u20131047.","journal-title":"Lancet"},{"key":"16_CR12","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","volume":"18","author":"A Gramont de","year":"2000","unstructured":"de Gramont A, Figer A, Seymour M, et al.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000, 18: 2938\u20132947.","journal-title":"J Clin Oncol"},{"key":"16_CR13","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200009283431302","volume":"343","author":"LB Saltz","year":"2000","unstructured":"Saltz LB, Cox JV, Blanke C, et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000, 343: 905\u2013914.","journal-title":"N Engl J Med"},{"key":"16_CR14","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1200\/JCO.2001.19.8.2282","volume":"19","author":"PM Hoff","year":"2001","unstructured":"Hoff PM, Ansari R, Batist G, et al.: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001, 19: 2282\u20132292.","journal-title":"J Clin Oncol"},{"key":"16_CR15","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.2001.19.21.4097","volume":"19","author":"E Cutsem Van","year":"2001","unstructured":"Van Cutsem E, Twelves C, Cassidy J, et al.: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001, 19: 4097\u20134106.","journal-title":"J Clin Oncol"},{"key":"16_CR16","doi-asserted-by":"crossref","unstructured":"Anonymous: Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. Nordic Gastrointestinal Tumor Adjuvant Therapy Group. J Clin Oncol 1992, 10:904\u2013911.","DOI":"10.1200\/JCO.1992.10.6.904"},{"key":"16_CR17","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(98)02309-5","volume":"352","author":"D Cunningham","year":"1998","unstructured":"Cunningham D, Pyrhonen S, James RD, et al.: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998, 352: 1413\u20131418.","journal-title":"Lancet"},{"key":"16_CR18","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2004.11.037","volume":"22","author":"A Grothey","year":"2004","unstructured":"Grothey A, Sargent D, Goldberg RM, Schmoll HJ: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004, 22: 1209\u20131214. This study suggests that patients included in clinical trials who received fluorouracil, oxaliplatin, and irinotecan at some point during the disease course live longer.","journal-title":"J Clin Oncol"},{"key":"16_CR19","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","volume":"22","author":"C Tournigand","year":"2004","unstructured":"Tournigand C, Andre T, Achille E, et al.: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004, 22: 229\u2013237. This study from France demonstrates that patients may be treated with either oxaliplatin or irinotecan combinations in the first line, and receive the opposite in the second line.","journal-title":"J Clin Oncol"},{"key":"16_CR20","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1200\/JCO.1987.5.10.1559","volume":"5","author":"N Petrelli","year":"1987","unstructured":"Petrelli N, Herrera L, Rustum Y, et al.: A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 1987, 5: 1559\u20131565.","journal-title":"J Clin Oncol"},{"key":"16_CR21","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1200\/JCO.1989.7.10.1407","volume":"7","author":"MA Poon","year":"1989","unstructured":"Poon MA, O\u2019Connell MJ, Moertel CG, et al.: Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989, 7: 1407\u20131418.","journal-title":"J Clin Oncol"},{"key":"16_CR22","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1200\/JCO.1996.14.11.2959","volume":"14","author":"LB Saltz","year":"1996","unstructured":"Saltz LB, Kanowitz J, Kemeny NE, et al.: Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. J Clin Oncol 1996, 14: 2959\u20132967.","journal-title":"J Clin Oncol"},{"key":"16_CR23","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1200\/JCO.2001.19.15.3456","volume":"19","author":"A Falcone","year":"2001","unstructured":"Falcone A, Di Paolo A, Masi G, et al.: Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients. J Clin Oncol 2001, 19: 3456\u20133462.","journal-title":"J Clin Oncol"},{"key":"16_CR24","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.clpt.2004.03.008","volume":"76","author":"SP Joel","year":"2004","unstructured":"Joel SP, Papamichael D, Richards F, et al.: Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin. Clin Pharmacol Ther 2004, 76: 45\u201354.","journal-title":"Clin Pharmacol Ther"},{"key":"16_CR25","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/sj.bjc.6601137","volume":"89","author":"K Brickell","year":"2003","unstructured":"Brickell K, Porter D, Thompson P: Phenytoin toxicity due to fluoropyrimidines (5FU\/capecitabine): three case reports. Br J Cancer 2003, 89: 615\u2013616.","journal-title":"Br J Cancer"},{"key":"16_CR26","doi-asserted-by":"crossref","unstructured":"Anonymous: Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group In Cancer. J Clin Oncol 1998, 16:3537\u20133541.","DOI":"10.1200\/JCO.1998.16.11.3537"},{"key":"16_CR27","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1592\/phco.19.18.1445.30897","volume":"19","author":"JM Kolesar","year":"1999","unstructured":"Kolesar JM, Johnson CL, Freeberg BL, et al.: Warfarin-5-FU interaction\u2014a consecutive case series. Pharmacotherapy 1999, 19: 1445\u20131449.","journal-title":"Pharmacotherapy"},{"key":"16_CR28","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1200\/JCO.2003.02.042","volume":"21","author":"G Masci","year":"2003","unstructured":"Masci G, Magagnoli M, Zucali PA, et al.: Minidose warfarin prophylaxis for catheter-associated thrombosis in cancer patients: can it be safely associated with fluorouracil-based chemotherapy? J Clin Oncol 2003, 21: 736\u2013739.","journal-title":"J Clin Oncol"},{"key":"16_CR29","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMp048143","volume":"351","author":"D Schrag","year":"2004","unstructured":"Schrag D: The price tag on progress\u2014chemotherapy for colorectal cancer. N Engl J Med 2004, 351: 317\u2013319.","journal-title":"N Engl J Med"},{"key":"16_CR30","doi-asserted-by":"crossref","first-page":"895","DOI":"10.2165\/00003495-200060040-00005","volume":"60","author":"CR Culy","year":"2000","unstructured":"Culy CR, Clemett D, Wiseman LR: Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs 2000, 60: 895\u2013924.","journal-title":"Drugs"},{"key":"16_CR31","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00000421-199806000-00015","volume":"21","author":"F deBraud","year":"1998","unstructured":"deBraud F, Munzone E, Nole F, et al.: Synergistic activity of oxaliplatin and 5-fluorouracil in patients with metastatic colorectal cancer with progressive disease while on or after 5-fluorouracil. Am J Clin Oncol 1998, 21: 279\u2013283.","journal-title":"Am J Clin Oncol"},{"key":"16_CR32","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1200\/JCO.2004.09.046","volume":"22","author":"RM Goldberg","year":"2004","unstructured":"Goldberg RM, Sargent DJ, Morton RF, et al.: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004, 22: 23\u201330. This important phase III trial established the FOLFOX4 regimen as an alternative in the first-line treatment of patients with metastatic disease.","journal-title":"J Clin Oncol"},{"key":"16_CR33","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1200\/JCO.2003.11.126","volume":"21","author":"ML Rothenberg","year":"2003","unstructured":"Rothenberg ML, Oza AM, Bigelow RH, et al.: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracilleucovorin: interim results of a phase III trial. J Clin Oncol 2003, 21: 2059\u20132069.","journal-title":"J Clin Oncol"},{"key":"16_CR34","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/01.COC.0000071383.39986.A4","volume":"27","author":"MA Gil-Delgado","year":"2004","unstructured":"Gil-Delgado MA, Bastian G, Guinet F, et al.: Oxaliplatin plus irinotecan and FU-FOL combination and pharmacokinetic analysis in advanced colorectal cancer patients. Am J Clin Oncol 2004, 27: 294\u2013298.","journal-title":"Am J Clin Oncol"},{"key":"16_CR35","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1158\/1078-0432.CCR-03-0666","volume":"10","author":"L Gamelin","year":"2004","unstructured":"Gamelin L, Boisdron-Celle M, Delva R, et al.: Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 2004, 10: 4055\u20134061.","journal-title":"Clin Cancer Res"},{"key":"16_CR36","first-page":"1","volume":"5","author":"M Lloyd Jones","year":"2001","unstructured":"Lloyd Jones M, Hummel S, Bansback N, et al.: A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. Health Technol Assess 2001, 5: 1\u2013128.","journal-title":"Health Technol Assess"},{"key":"16_CR37","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2165\/00003495-199549010-00002","volume":"49","author":"BK Sinha","year":"1995","unstructured":"Sinha BK: Topoisomerase inhibitors. A review of their therapeutic potential in cancer. Drugs 1995, 49: 11\u201319.","journal-title":"Drugs"},{"key":"16_CR38","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1200\/JCO.2003.08.058","volume":"21","author":"CS Fuchs","year":"2003","unstructured":"Fuchs CS, Moore MR, Harker G, et al.: Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 2003, 21: 807\u2013814.","journal-title":"J Clin Oncol"},{"key":"16_CR39","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1200\/JCO.2002.08.177","volume":"20","author":"DF Kehrer","year":"2002","unstructured":"Kehrer DF, Mathijssen RH, Verweij J, et al.: Modulation of irinotecan metabolism by ketoconazole. J Clin Oncol 2002, 20: 3122\u20133129.","journal-title":"J Clin Oncol"},{"key":"16_CR40","first-page":"33","volume":"16","author":"JG Kuhn","year":"2002","unstructured":"Kuhn JG: Influence of anticonvulsants on the metabolism and elimination of irinotecan. A North American Brain Tumor Consortium preliminary report. Oncology (Huntingt) 2002, 16: 33\u201340.","journal-title":"Oncology (Huntingt)"},{"key":"16_CR41","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/jnci\/94.16.1247","volume":"94","author":"RH Mathijssen","year":"2002","unstructured":"Mathijssen RH, Verweij J, de Bruijn P, et al.: Effects of St. John\u2019s wort on irinotecan metabolism. J Natl Cancer Inst 2002, 94: 1247\u20131249.","journal-title":"J Natl Cancer Inst"},{"key":"16_CR42","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1200\/JCO.2001.19.18.3801","volume":"19","author":"ML Rothenberg","year":"2001","unstructured":"Rothenberg ML, Meropol NJ, Poplin EA, et al.: Mortality associated with irinotecan plus bolus fluorouracil\/ leucovorin: summary findings of an independent panel. J Clin Oncol 2001, 19: 3801\u20133807.","journal-title":"J Clin Oncol"},{"key":"16_CR43","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1200\/JCO.2004.04.132","volume":"22","author":"AB Benson 3rd","year":"2004","unstructured":"Benson AB 3rd, Ajani JA, Catalano RB, et al.: Recommended guidelines for the treatment of cancer treatmentinduced diarrhea. J Clin Oncol 2004, 22: 2918\u20132926.","journal-title":"J Clin Oncol"},{"key":"16_CR44","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1023\/A:1008261821434","volume":"8","author":"E Wasserman","year":"1997","unstructured":"Wasserman E, Myara A, Lokiec F, et al.: Severe CPT-11 toxicity in patients with Gilbert\u2019s syndrome: two case reports. Ann Oncol 1997, 8: 1049\u20131051.","journal-title":"Ann Oncol"},{"key":"16_CR45","first-page":"640","volume":"26","author":"PM Hoff","year":"1999","unstructured":"Hoff PM, Royce M, Medgyesy D, et al.: Oral fluoropoyrimidines. Semin Oncol 1999, 26: 640\u2013646.","journal-title":"Semin Oncol"},{"key":"16_CR46","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2165\/00003495-199958010-00006","volume":"58","author":"M Dooley","year":"1999","unstructured":"Dooley M, Goa KL: Capecitabine. Drugs 1999, 58: 69\u201376, discussion 77\u201378.","journal-title":"Drugs"},{"key":"16_CR47","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s002800050043","volume":"45","author":"J Schuller","year":"2000","unstructured":"Schuller J, Cassidy J, Dumont E, et al.: Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000, 45: 291\u2013297.","journal-title":"Cancer Chemother Pharmacol"},{"key":"16_CR48","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1200\/JCO.1998.16.9.2977","volume":"16","author":"M Mackean","year":"1998","unstructured":"Mackean M, Planting A, Twelves C, et al.: Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and\/ or metastatic cancer. J Clin Oncol 1998, 16: 2977\u20132985.","journal-title":"J Clin Oncol"},{"key":"16_CR49","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/sj.bjc.6601676","volume":"90","author":"E Cutsem Van","year":"2004","unstructured":"Van Cutsem E, Hoff PM, Harper P, et al.: Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 2004, 90: 1190\u20131197. This combined analysis of two phase III trials provides a summary of the comparative efficacy between capecitabine and fluorouracil.","journal-title":"Br J Cancer"},{"key":"16_CR50","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1081\/CNV-120000360","volume":"20","author":"S Abushullaih","year":"2002","unstructured":"Abushullaih S, Saad ED, Munsell M, Hoff PM: Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a singleinstitution experience. Cancer Invest 2002, 20: 3\u201310.","journal-title":"Cancer Invest"},{"key":"16_CR51","first-page":"31","volume":"16","author":"E Lin","year":"2002","unstructured":"Lin E, Morris JS, Ayers GD: Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. Oncology (Huntingt) 2002, 16: 31\u201337.","journal-title":"Oncology (Huntingt)"},{"key":"16_CR52","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF00216925","volume":"8","author":"CJ Fabian","year":"1990","unstructured":"Fabian CJ, Molina R, Slavik M, et al.: Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Invest New Drugs 1990, 8: 57\u201363.","journal-title":"Invest New Drugs"},{"key":"16_CR53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta7320","volume":"7","author":"S Ward","year":"2003","unstructured":"Ward S, Kaltenthaler E, Cowan J, Brewer N: Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation. Health Technol Assess 2003, 7: 1\u201393.","journal-title":"Health Technol Assess"},{"key":"16_CR54","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0149-2918(04)90060-4","volume":"26","author":"FG Jansman","year":"2004","unstructured":"Jansman FG, Postma MJ, van Hartskamp D, et al.: Cost-benefit analysis of capecitabine versus 5-fluorouracil\/ leucovorin in the treatment of colorectal cancer in the Netherlands. Clin Ther 2004, 26: 579\u2013589.","journal-title":"Clin Ther"},{"key":"16_CR55","first-page":"736","volume":"18","author":"PM Hoff","year":"2004","unstructured":"Hoff PM, Ellis LM, Abbruzzese JL: Monoclonal antibodies: the foundation of therapy for colorectal cancer in the 21st century? Oncology (Huntingt) 2004, 18: 736\u201341, discussion 742, 745\u20136.","journal-title":"Oncology (Huntingt)"},{"key":"16_CR56","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrd1381","volume":"3","author":"N Ferrara","year":"2004","unstructured":"Ferrara N, Hillan KJ, Gerber HP, Novotny W: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004, 3: 391\u2013400.","journal-title":"Nat Rev Drug Discov"},{"key":"16_CR57","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1200\/JCO.2003.10.066","volume":"21","author":"F Kabbinavar","year":"2003","unstructured":"Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al.: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)\/leucovorin (LV) with FU\/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003, 21: 60\u201365.","journal-title":"J Clin Oncol"},{"key":"16_CR58","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350: 2335\u20132342. This is the first phase III trial to demonstrate that an antiangiogenic agent provides a survival advantage in any tumor type.","journal-title":"N Engl J Med"},{"key":"16_CR59","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1677\/erc.0.0080003","volume":"8","author":"J Mendelsohn","year":"2001","unstructured":"Mendelsohn J: The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer 2001, 8: 3\u20139.","journal-title":"Endocr Relat Cancer"},{"key":"16_CR60","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1200\/JCO.2004.10.182","volume":"22","author":"LB Saltz","year":"2004","unstructured":"Saltz LB, Meropol NJ, Loehrer PJ, Sr., et al.: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004, 22: 1201\u20131208.","journal-title":"J Clin Oncol"},{"key":"16_CR61","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","volume":"351","author":"D Cunningham","year":"2004","unstructured":"Cunningham D, Humblet Y, Siena S, et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351: 337\u2013345.","journal-title":"N Engl J Med"}],"container-title":["Current Treatment Options in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-005-0016-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11938-005-0016-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-005-0016-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:57:01Z","timestamp":1559437021000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11938-005-0016-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["16"],"URL":"https:\/\/doi.org\/10.1007\/s11938-005-0016-x","relation":{},"ISSN":["1092-8472","1534-309X"],"issn-type":[{"value":"1092-8472","type":"print"},{"value":"1534-309X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6]]}}}